Published January 1, 2016
| Version v1
Journal article
Open
K-Ras4B/calmodulin/PI3Ka: A promising new adenocarcinoma-specific drug target?
Creators
- 1. Koc Univ, Dept Chem & Biol Engn, Istanbul, Turkey
- 2. NCI, Frederick Natl Lab Canc Res, Leidos Biomed Res Inc, Canc & Inflammat Program, Frederick, MD USA
- 3. Koc Univ, Dept Comp Engn, Istanbul, Turkey
Description
Introduction: Decades of efforts have yet to yield a safe and effective drug to target KRAS-driven pancreatic, colorectal and lung cancers; particularly those driven by the highly oncogenic splice variant KRAS4B. K-Ras4B's fairly smooth surface, cancer tissue/cell heterogeneity, tolerated lipid post-translational modification exchange, as well as drug-elicited toxicity present a daunting challenge.
Files
bib-d999b9d6-4cd8-4aa7-99b5-38e7196b1df4.txt
Files
(217 Bytes)
| Name | Size | Download all |
|---|---|---|
|
md5:e605efef19514e7f1ac6abd5b4701727
|
217 Bytes | Preview Download |